127 related articles for article (PubMed ID: 28008665)
21. Ligand-based computer aided drug design reveals new tropomycin receptor kinase a (TrkA) inhibitors.
Shahin R; Mansi I; Swellmeen L; Alwidyan T; Al-Hashimi N; Al-Qarar'h Y; Shaheen O
J Mol Graph Model; 2018 Mar; 80():327-352. PubMed ID: 29454290
[TBL] [Abstract][Full Text] [Related]
22. Elaborate ligand-based modeling reveals new nanomolar heat shock protein 90α inhibitors.
Al-Sha'er MA; Taha MO
J Chem Inf Model; 2010 Sep; 50(9):1706-23. PubMed ID: 20831219
[TBL] [Abstract][Full Text] [Related]
23. Extensive ligand-based modeling and in silico screening reveal nanomolar inducible nitric oxide synthase (iNOS) inhibitors.
Suaifan GA; Shehadehh M; Al-Ijel H; Taha MO
J Mol Graph Model; 2012 Jul; 37():1-26. PubMed ID: 22609742
[TBL] [Abstract][Full Text] [Related]
24. Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors.
Shahin R; Alqtaishat S; Taha MO
J Comput Aided Mol Des; 2012 Feb; 26(2):249-66. PubMed ID: 22167443
[TBL] [Abstract][Full Text] [Related]
25. Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.
Taha MO; Bustanji Y; Al-Ghussein MA; Mohammad M; Zalloum H; Al-Masri IM; Atallah N
J Med Chem; 2008 Apr; 51(7):2062-77. PubMed ID: 18324764
[TBL] [Abstract][Full Text] [Related]
26. Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling.
Al-Najjar BO; Wahab HA; Tengku Muhammad TS; Shu-Chien AC; Ahmad Noruddin NA; Taha MO
Eur J Med Chem; 2011 Jun; 46(6):2513-29. PubMed ID: 21482446
[TBL] [Abstract][Full Text] [Related]
27. Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors.
Taha MO; Dahabiyeh LA; Bustanji Y; Zalloum H; Saleh S
J Med Chem; 2008 Oct; 51(20):6478-94. PubMed ID: 18808096
[TBL] [Abstract][Full Text] [Related]
28. Ligand-based computational modelling of platelet-derived growth factor beta receptor leading to new angiogenesis inhibitory leads.
Al-Aqtash RA; Zihlif MA; Hammad H; Nassar ZD; Meliti JA; Taha MO
Comput Biol Chem; 2017 Dec; 71():170-179. PubMed ID: 29101826
[TBL] [Abstract][Full Text] [Related]
29. Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent beta-secretase inhibitory leads.
Al-Nadaf A; Abu Sheikha G; Taha MO
Bioorg Med Chem; 2010 May; 18(9):3088-115. PubMed ID: 20378363
[TBL] [Abstract][Full Text] [Related]
30. IKKβ inhibitor identification: a multi-filter driven novel scaffold.
Nagarajan S; Choo H; Cho YS; Shin KJ; Oh KS; Lee BH; Pae AN
BMC Bioinformatics; 2010 Oct; 11 Suppl 7(Suppl 7):S15. PubMed ID: 21106122
[TBL] [Abstract][Full Text] [Related]
31. Discovery of new β-D-galactosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening.
Abdula AM; Khalaf RA; Mubarak MS; Taha MO
J Comput Chem; 2011 Feb; 32(3):463-82. PubMed ID: 20730780
[TBL] [Abstract][Full Text] [Related]
32. Elaborate ligand-based modeling coupled with multiple linear regression and k nearest neighbor QSAR analyses unveiled new nanomolar mTOR inhibitors.
Khanfar MA; Taha MO
J Chem Inf Model; 2013 Oct; 53(10):2587-612. PubMed ID: 24050502
[TBL] [Abstract][Full Text] [Related]
33. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening.
Al-Masri IM; Mohammad MK; Taha MO
ChemMedChem; 2008 Nov; 3(11):1763-79. PubMed ID: 18989859
[TBL] [Abstract][Full Text] [Related]
34. IKK-beta inhibitors: an analysis of drug-receptor interaction by using molecular docking and pharmacophore 3D-QSAR approaches.
Lauria A; Ippolito M; Fazzari M; Tutone M; Di Blasi F; Mingoia F; Almerico AM
J Mol Graph Model; 2010 Aug; 29(1):72-81. PubMed ID: 20537930
[TBL] [Abstract][Full Text] [Related]
35. Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors.
Abu Hammad AM; Taha MO
J Chem Inf Model; 2009 Apr; 49(4):978-96. PubMed ID: 19341295
[TBL] [Abstract][Full Text] [Related]
36. Combination of pharmacophore model development and binding mode analyses: identification of ligand features essential for IκB kinase-beta (IKKβ) inhibitors and virtual screening based on it.
Sun HP; Zhu J; Chen FH; Zhang SL; Zhang Y; You QD
Eur J Med Chem; 2011 Sep; 46(9):3942-52. PubMed ID: 21708416
[TBL] [Abstract][Full Text] [Related]
37. Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening.
Taha MO; Atallah N; Al-Bakri AG; Paradis-Bleau C; Zalloum H; Younis KS; Levesque RC
Bioorg Med Chem; 2008 Feb; 16(3):1218-35. PubMed ID: 17988876
[TBL] [Abstract][Full Text] [Related]
38. Pharmacophore and QSAR Modeling of Neuronal Nitric Oxide Synthase Ligands and Subsequent Validation and In Silico Search for New Scaffolds.
Suaifan G; Shehadeh M; Al-Ijel H; Al-Jamal KT; Taha M
Med Chem; 2016; 12(4):371-93. PubMed ID: 26427928
[TBL] [Abstract][Full Text] [Related]
39. Ligand-based modeling of diverse aryalkylamines yields new potent P-glycoprotein inhibitors.
AlQudah DA; Zihlif MA; Taha MO
Eur J Med Chem; 2016 Mar; 110():204-23. PubMed ID: 26840362
[TBL] [Abstract][Full Text] [Related]
40. Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration.
Abu Khalaf R; Abu Sheikha G; Bustanji Y; Taha MO
Eur J Med Chem; 2010 Apr; 45(4):1598-617. PubMed ID: 20116902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
